Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 1/20 | 0.56 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.56 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.56 |
| ▸ | IGF2R | P11717 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | GJA1 | P17302 | 1/20 | 0.49 |
| ▸ | GJB2 | P29033 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | AMY2A | P04746 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maltose SCHEMBL13739566 | 1.00 | LGALS8 (0.56) | LGALS8LGALS3LGALS4IGF2RMEN1 | |
| SCHEMBL13738934 | 1.00 | LGALS8 (0.56) | LGALS8LGALS3LGALS4IGF2RMEN1 | |
| Cellobiose SCHEMBL5382442 | 0.91 | LGALS8 (0.58) | LGALS8LGALS3LGALS4IGF2RMEN1 | |
| Cellobiose SCHEMBL25382543 | 0.91 | LGALS8 (0.61) | LGALS8LGALS3LGALS4IGF2RMEN1 | |
| Cellobiose SCHEMBL24662526 | 0.91 | LGALS8 (0.61) | LGALS8LGALS3LGALS4IGF2RMEN1 | |
| Cellobiose SCHEMBL23708014 | 0.91 | LGALS8 (0.61) | LGALS8LGALS3LGALS4IGF2RMEN1 | |
| Cellobiose SCHEMBL24202679 | 0.91 | LGALS8 (0.61) | LGALS8LGALS3LGALS4IGF2RMEN1 | |
| Cellobiose SCHEMBL21511124 | 0.91 | LGALS8 (0.61) | LGALS8LGALS3LGALS4IGF2RMEN1 | |
| Maltotriose SCHEMBL20553487 | 0.91 | LGALS8 (0.61) | LGALS8LGALS3LGALS4IGF2RMEN1 | |
| Cellobiose SCHEMBL21114355 | 0.91 | LGALS8 (0.61) | LGALS8LGALS3LGALS4IGF2RMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140228543-A1 | MODIFIED AND DERIVATIZED ß-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS | MIDCAP FINANCIAL TRUST, AS AGENT | 2014-08-14 | — | — | US | disclosed |
| WO-2012154680-A2 | MODIFIED AND DERIVATIZED β-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS | BIOTHERA, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228543-A1 | MODIFIED AND DERIVATIZED ß-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS | MANBA, ALG1, MAN2A1 | LGALS8 52/4885LGALS3 35/4885LGALS4 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.